CD8A and neoplasm: The tumour expression of any of the immune response genes was not found to impact on patient outcome on its own, with the exception of tumour positive CD8 mRNA expression, for which a trend for reduced risk for relapse was seen (HR = 0.51, 95% CI 0.26–0.99, Wald’s p = 0.05).